share_log

Oncternal Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $14 price target.

Oncternal Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $14 price target.

在奥本海默以优于大盘的评级对该股进行覆盖并宣布14美元的目标价后,Oncternal治疗公司的股价上涨。
Benzinga ·  2021/04/07 19:32

Oncternal Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $14 price target.

在奥本海默以优于大盘的评级对该股进行覆盖并宣布14美元的目标价后,Oncternal治疗公司的股价上涨。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发